Core Viewpoint - A securities class action lawsuit has been filed against Ardent Health, Inc. following significant adverse accounting adjustments of approximately $90 million, leading to a stock price decline of over 33% [1] Group 1: Lawsuit Details - The lawsuit seeks to represent investors who acquired Ardent securities between July 18, 2024, and November 12, 2025 [1] - The lead plaintiff deadline for the lawsuit is set for March 9, 2026 [3] - The case is titled Postiwala v. Ardent Health, Inc. et al., No. 3:26-cv-00022 (M.D. Tenn.) [3] Group 2: Allegations and Investigations - Hagens Berman is investigating claims that Ardent's leadership failed to disclose material weaknesses in internal controls related to revenue recognition and liability reserves [2] - The complaint alleges that timely writing off uncollectible accounts is crucial to avoid inflating accounts receivable [4] - The lawsuit claims that Ardent misled investors regarding its reliance on detailed reviews of historical collections for determining accounts receivable collectability [5] Group 3: Financial Disclosures and Market Reaction - On November 12, 2025, Ardent disclosed a $42.6 million decrease in revenue due to changes in accounting estimates and new information from hindsight evaluations [6] - The CFO revealed that the company's collectability framework used a 180-day cliff for reserving accounts, contradicting earlier assurances [6] - Following the disclosures, Ardent's stock price fell by $4.75, a decline of 33% [6] Group 4: Implications and Further Actions - The significant revenue reduction of $43 million and reserve increase of $54 million raises questions about whether these issues should have been disclosed earlier [7] - Investors who suffered losses are encouraged to contact Hagens Berman for potential recovery options [7]

Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant financial losses for investors during the specified class period [1][3]. Company Overview - Ardent Health, Inc. operates a network of hospitals and clinics providing various healthcare services [2]. Allegations of the Lawsuit - The lawsuit claims that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, which allowed the company to report inflated financial figures [3]. - It is alleged that Ardent Health's accounts receivable framework utilized a "180-day cliff" for reserving accounts, delaying the recognition of losses on uncollectible accounts [3]. - The company reportedly lacked sufficient professional malpractice liability insurance and reserves to cover claims, particularly in light of increasing social inflationary pressures in the New Mexico market [3]. Financial Impact - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised accounts receivable collectability assessments and a new revenue accounting system [4]. - The company also cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. - Additionally, a $54 million increase in professional liability reserves was recorded due to recent settlements and ongoing litigation, reflecting broader industry trends [4]. - Following these announcements, Ardent Health's stock price fell nearly 34% [4]. Legal Process - Investors who purchased Ardent Health securities during the class period can seek to be appointed as lead plaintiff in the lawsuit, representing the interests of the class [5]. - The lead plaintiff has the authority to select a law firm for litigation and does not need to be the lead plaintiff to share in any potential recovery [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has a strong track record in obtaining significant recoveries in securities class action cases, including the largest recovery in history [6].

Faruqi & Faruqi, LLP also encourages anyone with information regarding Ardent's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ardent Health (ARDT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Ardent Health securities between July 18, 2024 and November 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- What’s Ha ...

Core Viewpoint - A class action lawsuit has been filed against Ardent Health, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is filed in the U.S. District Court for the Middle District of Tennessee, captioned Postiwala v. Ardent Health, Inc., et al., No. 3:26-cv-00022 [3]. - Investors have until March 9, 2026, to request to lead the case, with claims asserted under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Allegations Against Ardent Health - The lawsuit alleges that Ardent Health misrepresented its process for determining the collectability of accounts receivable, claiming reliance on "detailed reviews of historical collections" while actually using a "180-day cliff" method [4]. - This misrepresentation allowed Ardent Health to report inflated accounts receivable and delay recognizing losses on uncollectable accounts, constituting a violation of federal securities laws [4]. Group 3: Stock Price Impact - On November 12, 2025, Ardent Health announced a $43 million revenue decrease for the quarter and a $54 million increase in professional liability reserves, leading to a stock price drop of $4.75 per share, or over 33%, from $14.05 to $9.30 [5].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2025, and November 12, 2025, alleging that the company misled investors regarding its accounts receivable [1][2]. Allegations - The complaint states that Ardent Health reported inflated accounts receivable and delayed recognizing losses on uncollectible accounts [2]. - It is alleged that Ardent Health did not maintain sufficient professional malpractice liability insurance to cover claims arising from its operations [2]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised assessments of accounts receivable collectability, which led to a significant drop in stock price from $14.05 to $9.30 per share, a decline of nearly 34% [2]. Next Steps - Shareholders interested in serving as lead plaintiffs in the class action against Ardent Health, Inc. are encouraged to contact Robbins LLP [3]. - Shareholders can choose to remain absent class members without participating in the case while still being eligible for recovery [3].

NEW YORK--(BUSINESS WIRE)---- $ARDT #ARDT--BFA Law has Sued Ardent Health, Inc. for Securities Fraud after Collectability Issues lead to 33% Stock Drop -- Investors Notified to Contact the Firm. ...

Core Insights - The healthcare sector is facing regulatory shifts and economic pressures, impacting hospitals' operations and financial performance [1] - Bank of America (BofA) Securities expresses caution regarding hospitals due to moderating fundamentals and a restrictive policy environment, predicting a 2-4% EBITDA headwind to growth annually for the next five years [2] - BofA highlights that while some new state-directed payment programs may be approved, the quality of EBITDA growth is expected to be low due to future cuts [3] Company-Specific Analysis - Universal Health Services Inc. (UHS) and Ardent Health Inc. (ARDT) are anticipated to be most adversely affected, while HCA Healthcare Inc. (HCA) is positioned to better withstand these headwinds [4] - The demand for hospital services is stabilizing, but policy changes are expected to create a 90 basis points headwind in 2026, likely resulting in volumes falling below long-term growth expectations [5] - The fourth quarter of 2025 may see increased volume due to demand pull-forward ahead of coverage changes, creating a challenging comparison for 2026 [6] Investment Preferences - BofA prefers post-acute care companies, with Encompass Health Corporation (EHC) identified as a top pick due to its minimal exposure to upcoming cuts [6][7] - Tenet Healthcare Corporation (THC) is highlighted as a top pick among hospitals, benefiting from its ambulatory surgery centers' exposure, which insulates it from the impacts of the Reconciliation Bill [8] - Brookdale Senior Living Inc. (BKD) has been upgraded to Buy from Underperform, reflecting improved free cash flow and favorable positioning in the aging demographics sector [9][10]

Core Viewpoint - The law firm Kirby McInerney LLP is investigating Ardent Health, Inc. for potential violations of federal securities laws or other unlawful business practices by the company or its senior management [1] Group 1 - On November 12, 2025, Ardent Health, Inc. announced its financial results for the third quarter [1]

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Ardent and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On November 12, ...